Checked
Cancer (all types) Clinical Trials in New Mexico
Open studies with at least one site in the state
Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.
- Open studies
- 163
- With a site in New Mexico
- Most studies in
- Albuquerque
- 46 of the studies shown
Studies
50 of 163, recruiting studies first. Cities are where the study lists a New Mexico site.
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingPhase 3NCT04181060· National Cancer Institute (NCI)
Albuquerque
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3NCT04267848· National Cancer Institute (NCI)
Albuquerque, Rio Rancho
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingPhase 3NCT04269902· National Cancer Institute (NCI)
Albuquerque, Las Cruces, Rio Rancho
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2NCT05136196· National Cancer Institute (NCI)
Albuquerque
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT05554393· National Cancer Institute (NCI)
Albuquerque
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT05554406· National Cancer Institute (NCI)
Albuquerque
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2NCT05564377· National Cancer Institute (NCI)
Albuquerque
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2NCT05564390· National Cancer Institute (NCI)
Albuquerque
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2NCT06124157· National Cancer Institute (NCI)
Albuquerque
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingPhase 3NCT06172296· National Cancer Institute (NCI)
Albuquerque
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT06317649· National Cancer Institute (NCI)
Albuquerque
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingPhase 3NCT06422806· National Cancer Institute (NCI)
Albuquerque
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT06672146· National Cancer Institute (NCI)
Albuquerque
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NCT05327686· NRG Oncology
Albuquerque
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingPhase 2NCT05408845· NRG Oncology
Albuquerque
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingPhase 3NCT05920356· Amgen
Albuquerque
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerRecruitingPhase 3NCT05946213· NRG Oncology
Albuquerque
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3NCT06561386· Bristol-Myers Squibb
Albuquerque
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingPhase 2, Phase 3NCT06943755· Exelixis
Albuquerque
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3NCT06943872· BeOne Medicines
Santa Fe
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3NCT07060807· Merck Sharp & Dohme LLC
Albuquerque, Rio Rancho
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingPhase 3NCT07198074· National Cancer Institute (NCI)
Albuquerque
- Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having CancerRecruitingNCT03977402· New Mexico Cancer Research Alliance
Albuquerque
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingPhase 2NCT04671667· National Cancer Institute (NCI)
Albuquerque
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingPhase 2NCT05112601· National Cancer Institute (NCI)
Albuquerque
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingPhase 2, Phase 3NCT05139017· Merck Sharp & Dohme LLC
Rio Rancho
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerRecruitingPhase 1NCT05950464· National Cancer Institute (NCI)
Albuquerque
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group StudiesRecruitingNCT00736749· Children's Oncology Group
Albuquerque
- Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome SequencingRecruitingNCT06207864· New Mexico Cancer Research Alliance
Albuquerque
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingPhase 2NCT06890338· AbbVie
Albuquerque
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingPhase 2, Phase 3NCT07365319· Eikon Therapeutics
Albuquerque
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2NCT02523014· Alliance for Clinical Trials in Oncology
Albuquerque
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3NCT03150693· Alliance for Clinical Trials in Oncology
Albuquerque
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3NCT04928846· AbbVie
Farmington
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruitingPhase 3NCT06498635· National Cancer Institute (NCI)
Albuquerque
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3NCT07611110· AstraZeneca
Albuquerque
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2NCT05633615· SWOG Cancer Research Network
Albuquerque
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingPhase 3NCT06422143· Merck Sharp & Dohme LLC
Albuquerque
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruitingPhase 3NCT06855277· Novartis Pharmaceuticals
Albuquerque
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)RecruitingPhase 3NCT06925737· Merck Sharp & Dohme LLC
Albuquerque
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingPhase 3NCT07214779· Incyte Corporation
Albuquerque
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingPhase 3NCT07711002· AstraZeneca
Albuquerque
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingPhase 1, Phase 2NCT05123482· AstraZeneca
Albuquerque
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingPhase 3NCT05633654· Gilead Sciences
Albuquerque, Farmington
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3NCT05774951· AstraZeneca
Farmington, Santa Fe
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingPhase 3NCT06393374· Merck Sharp & Dohme LLC
Albuquerque, Santa Fe
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingPhase 3NCT06467357· AstraZeneca
Albuquerque
- A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingPhase 3NCT06646276· Bristol-Myers Squibb
Albuquerque
- Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine CancerRecruitingPhase 1NCT06795009· Washington University School of Medicine
Albuquerque
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)RecruitingPhase 3NCT06824467· Merck Sharp & Dohme LLC
Albuquerque
Other cancer studies in New Mexico
Frequently asked questions
- Are there cancer (all types) clinical trials in New Mexico?
- Yes. 163 cancer (all types) studies on ClinicalTrials.gov list at least one site in New Mexico and are recruiting, about to recruit or enrolling by invitation, including sites in Albuquerque, Rio Rancho, Santa Fe.
- What does recruiting mean?
- Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
- How do I join a clinical trial?
- Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.
Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/26/2026